The Equity Group and Walbrook PR are handling Spectral MD as the AI company focused on predictive medical diagnostics merges with Rosecliff Acquisition Corp. in a SPAC deal valued at $170M.

Dallas-based Spectral MD plans to use the proceeds of the SPAC to pursue commercial opportunities in the US and UK for its burn and diabetic foot ulcer indications.

It also sees significant US government business for its DeepView wound diagnostic platform for mass casualty events.

Spectral MD has already received $125M in contracts from various federal agencies for DeepView.

As part of the transaction, Spectral MD will delist its shares from the London Stock Exchange and trade on the NASDAQ.

The merged company will be renamed Spectral AI.

The Equity Group’s Devin Sullivan handles the US investment community for the deal, while Walbrook PR’s Paul McManus, Alice Wooding and Louis Ashe-Jepson provide IR and media services in the UK.